This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Grey platelet syndrome그레이혈소판증후군

ICD-10: D69.1 | Synonyms: GPS, Grey platelet syndrome, Alpha granule deficiency, Gray platelet syndrome

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

First description

Grey platelet syndrome was first described in 1971 by Raccuglia, who noted that platelets in a Wright-Giemsa stain smear from a patient with a bleeding tendency had a pale grayish appearance. Electron microscopy later confirmed that the reason platelets take on a characteristic grayish color, rather than staining the normal purple-pink, is a deficiency of platelet alpha granules.

Identification of alpha granule deficiency

In the late 1970s, Levy-Toledano et al. confirmed by electron microscopy that alpha granules are markedly reduced or absent in the platelets of GPS patients. Alpha granules are the most abundant organelles in platelets and store fibrinogen, vWF, P-selectin, platelet factor 4 (PF4), β-thromboglobulin, and other proteins.

Discovery of the NBEAL2 gene

In 2011, three research groups, including Gunay-Aygun et al., independently and simultaneously reported that mutations in the NBEAL2 (neurobeachin-like protein 2) gene cause GPS. NBEAL2 encodes a BEACH domain protein essential for the formation and maintenance of alpha granules, and this discovery first elucidated the molecular pathology of GPS.

2. Causes

NBEAL2 gene mutations

Classic GPS (autosomal recessive form) is caused by homozygous or compound heterozygous mutations in the NBEAL2 gene (located at 3p21.31). The NBEAL2 protein contains BEACH and WD40 domains involved in intracellular organelle membrane fusion and alpha granule formation.

Other genetic causes

Variants in genes other than NBEAL2 have been reported in some GPS patients: an autosomal dominant form of GPS caused by GFI1B (growth factor-independent 1B, 9q34.13) variants has been reported, accompanied by thrombocytopenia and alpha granule deficiency. GATA-1 variants can also produce a phenotype similar to alpha granule deficiency.

Acquired alpha granule deficiency

Besides the congenital form, alpha granule deficiency can be acquired in myeloproliferative neoplasms such as myelofibrosis, polycythemia vera, and essential thrombocythemia. Such cases are distinguished as acquired GPS-like states.

3. Genetics

Mode of inheritance

Classic GPS (NBEAL2 variants) is inherited in an autosomal recessive manner. Heterozygous carriers may show a mild reduction in platelet alpha granules but usually have no clinical bleeding symptoms. GPS due to GFI1B variants is inherited in an autosomal dominant manner.

Spectrum of NBEAL2 gene variants

A variety of NBEAL2 missense, nonsense, frameshift, and splicing variants have been reported worldwide. Most are unique variants found in individual families (private mutations), and recurrent variants within the same ethnic group (founder variants) are relatively rare.

GFI1B-related GPS

GFI1B gene mutations cause autosomal dominant GPS. GFI1B is a transcription factor involved in megakaryocyte differentiation and platelet production, and dominant-negative mutations in this gene cause alpha granule deficiency and thrombocytopenia.

4. General epidemiology

Worldwide prevalence

GPS is a very rare disease, documented in only about 50–100 families worldwide. An accurate prevalence estimate is difficult, but it is extremely rare, at less than 1 per 10 million. Case reports have been increasing since 2011, when molecular diagnosis became possible.

Racial and regional distribution

No specific ethnic distribution is clear, but incidence may be relatively higher in populations where consanguineous marriage is common. It has been reported in diverse regions, including Europe, North America, Japan, the Middle East, and India.

Status in Korea

In Korea, GPS is an extremely rare disease with very few reported cases. It is included in the national rare disease registration system, and patients with unexplained grayish platelets and a bleeding tendency need referral to a specialized center. With the spread of next-generation sequencing, molecular diagnosis is becoming available in Korea as well.

5. Pathophysiology

Role of normal alpha granules

Platelet alpha granules are the most abundant organelles in platelets (about 40–80 per platelet); upon platelet activation they secrete their granule proteins, which participate in hemostasis, coagulation, inflammation, and cell growth. Major alpha granule proteins: vWF, fibrinogen, fibronectin, vitronectin, P-selectin (CD62P), platelet factor 4 (PF4), β-thromboglobulin, thrombospondin, EGF, VEGF, PDGF, and others.

Abnormal alpha granule formation due to NBEAL2 deficiency

The NBEAL2 protein is essential for the maturation of alpha granule precursors from multivesicular bodies (MVB) in megakaryocytes. In NBEAL2 deficiency, alpha granule precursors fail to undergo proper sorting and maturation, and normal alpha granule formation fails. As a result, alpha granule proteins are released outside the platelet or accumulate in the extracellular matrix (bone marrow stroma).

Induction of bone marrow fibrosis

In GPS patients, myelofibrosis progresses as alpha granule growth factors such as PF4 and β-thromboglobulin are abnormally released into the bone marrow stroma. This is understood to be the mechanism of the bone marrow fibrosis characteristic of GPS. Bone marrow fibrosis worsens thrombocytopenia.

Platelet dysfunction

Alpha granule deficiency reduces granule secretion after platelet activation, so the secondary wave of platelet aggregation is impaired and the capacity to form a hemostatic plug is reduced.

6. Symptoms

Bleeding symptoms

The bleeding tendency in GPS ranges from mild to moderate and is generally milder than in Glanzmann thrombasthenia or BSS. Main symptoms: epistaxis (most common), gum bleeding, cutaneous petechiae and purpura, menorrhagia (in women). Excessive bleeding after surgery, tooth extraction, or trauma. Spontaneous severe bleeding (intracranial hemorrhage, gastrointestinal bleeding) is relatively rare but has been reported.

Symptoms related to bone marrow fibrosis

Worsening thrombocytopenia due to progressive bone marrow fibrosis. Fatigue due to anemia (decreased red blood cell production). Splenomegaly (extramedullary hematopoiesis). These symptoms require careful attention when differentiating GPS from myeloproliferative neoplasms.

Clinical course

Bleeding symptoms can appear early after birth, but diagnosis is often made in childhood to adolescence. Thrombocytopenia due to bone marrow fibrosis tends to progress with age.

7. Signs

Physical examination findings

Cutaneous petechiae, purpura, ecchymoses. Signs of intranasal bleeding. Pallor due to anemia. Splenomegaly (with progression of bone marrow fibrosis). Thrombocytopenia with increased platelet size (giant platelets).

Laboratory findings

Complete blood count (CBC): decreased platelet count (usually 40,000–100,000/μL), increased platelet size (increased MPV, giant platelets). Blood smear: platelets with a pale grayish appearance (pale gray, agranular platelets) — the origin of the name "grey platelet." PFA-100: prolonged closure time. Platelet aggregation testing: reduced aggregation in response to ADP, thrombin, and collagen (especially loss of the secondary wave). Ristocetin aggregation normal or mildly reduced. Flow cytometry: markedly reduced P-selectin (CD62P) expression after platelet activation (a marker of alpha granule deficiency); CD41/CD61 normal. Electron microscopy: markedly reduced or absent alpha granules; dense granules normal.

Bone marrow examination

Bone marrow aspirate and biopsy: normal or increased number of megakaryocytes, megakaryocytes lacking alpha granules, progressive bone marrow fibrosis. The degree of bone marrow fibrosis is assessed by MF grade (WHO criteria 0–3). Negative JAK2, CALR, and MPL variants differentiate it from myeloproliferative neoplasms.

8. Screening

Screening targets

GPS should be suspected in the following cases: ① thrombocytopenia + giant platelets + bleeding tendency, ② grayish pale platelets (agranular gray platelets) on blood smear, ③ loss of the secondary wave in ADP/collagen aggregation, ④ findings of bone marrow fibrosis, ⑤ platelet dysfunction without another cause.

Basic screening tests

CBC + blood smear (to identify gray platelets). PFA-100 (prolonged closure time). Platelet aggregation testing. Platelet release testing (P-selectin expression, measurement of serotonin secretion).

Bone marrow examination

Bone marrow biopsy is performed to assess bone marrow fibrosis, and its gradual progression is followed. Differentiation from myeloproliferative neoplasms requires JAK2 V617F, CALR, and MPL variant testing.

9. Diagnosis

Confirmatory tests

Electron microscopy: A marked reduction or absence of alpha granules in platelets is the key finding required for confirmation (dense granules are normal). Flow cytometry: confirms loss of P-selectin (CD62P) expression after platelet activation. Increased release of alpha granule proteins (PF4, β-thromboglobulin) into plasma and decreased storage within platelets.

Molecular genetic testing

NBEAL2 gene sequencing (direct sequencing or NGS panel). GFI1B gene analysis (when a familial, autosomal dominant form is suspected). Parental testing after variant identification (segregation analysis).

Differential diagnosis

DiseaseSimilaritiesDifferences
MYH9-related platelet disorderGiant platelets, thrombocytopeniaLeukocyte inclusion bodies (Döhle bodies), normal alpha granules
Primary myelofibrosisBone marrow fibrosis, splenomegalyJAK2 V617F positive, acquired alpha granule deficiency
Platelet-type vWD / vWD 2BGiant platelets, thrombocytopeniaAccompanying vWF abnormality, increased ristocetin aggregation

10. Treatment

General supportive care

Antifibrinolytics (tranexamic acid): used for mucosal bleeding and perioperatively. DDAVP: shortens bleeding time in some patients through vWF release. Iron supplementation: corrects iron deficiency anemia due to chronic bleeding. Oral contraceptives: control of menorrhagia.

Platelet transfusion

Platelet transfusion is given for severe bleeding or surgery. GPS patients develop alloantibodies to platelet transfusion less often than patients with other diseases, but the possibility of alloimmunization with repeated transfusions should be considered.

Recombinant FVIIa

rFVIIa may be used as adjunctive hemostatic therapy in patients refractory to platelet transfusion or in surgery where platelet transfusion should be avoided.

Managing progression of bone marrow fibrosis

There is currently no treatment that directly reverses bone marrow fibrosis in GPS. When thrombocytopenia worsens, transfusion support and thrombopoietin receptor agonists (TPO-RA; eltrombopag, romiplostim) have been tried in some patients to increase platelet counts. Allogeneic HSCT may be considered when severe bone marrow fibrosis has developed, but experience is very limited.

HSCT

In severe GPS, allogeneic HSCT is a potentially curative option that can correct both platelet function and bone marrow fibrosis, but reported cases are rare. The benefits must be carefully weighed against the risks of transplantation.

11. Prognosis

Long-term prognosis

Bleeding symptoms in GPS are generally moderate or milder, and most patients survive into adulthood. Death from bleeding is rare, but life-threatening bleeding such as severe intracranial or gastrointestinal hemorrhage can occasionally occur. Worsening thrombocytopenia, anemia, and splenomegaly due to progressive bone marrow fibrosis affect long-term prognosis.

Rate of progression of bone marrow fibrosis

The rate of progression of bone marrow fibrosis in GPS varies among patients. In some it progresses slowly over decades, while others show rapid progression. Progression should be followed with regular bone marrow examinations.

12. Prevention

Avoidance of bleeding triggers

Avoid antiplatelet drugs such as aspirin and NSAIDs. Limit trauma and contact sports. Consult a hematologist and establish a hemostasis plan before surgery, procedures, or delivery.

Regular follow-up

Regular monitoring of platelet count and the degree of bone marrow fibrosis. Early detection of signs of progressing bone marrow fibrosis such as anemia and splenomegaly. Prompt evaluation when bleeding symptoms worsen.

Genetic counseling

Inform patients and families about the autosomal recessive (NBEAL2 variants) or autosomal dominant (GFI1B variants) mode of inheritance, recurrence risk, carrier testing, and the availability of prenatal genetic diagnosis.

Prevention of complications

Monitoring for alloimmunization with repeated platelet transfusions. Iron and folic acid supplementation to prevent anemia-related complications. Keep vaccinations up to date to prevent infection.

13. References

  1. Raccuglia G. Gray platelet syndrome: a variety of qualitative platelet disorder. Am J Med. 1971;51(6):818-828.
  2. Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet alpha-granules. Nat Genet. 2011;43(8):732-734.
  3. Albers CA, Cvejic A, Favier R, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet. 2011;43(8):735-737.
  4. Kahr WH, Hinckley J, Li L, et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet. 2011;43(8):738-740.
  5. Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev. 2007;21(1):21-36.
  6. Nurden P, Debili N, Coupry I, et al. Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood. 2011;118(22):5928-5937.
  7. Favier R, Raslova H. In search of a genotype-phenotype relationship in gray platelet syndrome. J Thromb Haemost. 2015;13(12):2188-2191.
  8. Monteferrario D, Bolar NA, Marneth AE, et al. A dominant-negative GFI1B mutation in the gray platelet syndrome. N Engl J Med. 2014;370(3):245-253.
  9. Krishnamurti L, Neglia JP, Naides SJ, et al. Hematopoietic stem cell transplant for gray platelet syndrome. Bone Marrow Transplant. 2001;28(8):807-808.
  10. Bottega R, Pecci A, De Candia E, et al. Correlation between platelet phenotype and NBEAL2 genotype in patients with congenital thrombocytopenia and alpha-granule deficiency. Haematologica. 2014;99(6):1026-1032.
  11. Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol. 2011;154(2):161-174.
  12. Gresele P, Falcinelli E, Bury L. Inherited platelet function disorders: algorithms for phenotypic and genetic investigation. Semin Thromb Hemost. 2016;42(3):292-305.